ProPhase Labs

Historical price data

ProPhase Labs is a publicly-traded, multi-faceted healthcare company with a mission to create a healthier world through bold action and data-driven insight. The company has successfully pivoted from its consumer health origins, generating significant revenue through its diagnostic labs and Nebula Genomics subsidiary, while strategically investing in longer-term, high-potential biopharma programs. Its strategy hinges on executional excellence, smart diversification, and leveraging synergies between its business segments—genomics, biopharma, and consumer products—to drive toward its stated ambition of becoming a multibillion-dollar enterprise.

A hybrid platform combining CLIA-certified laboratory infrastructure for diagnostic services, a whole genome sequencing and bioinformatics engine for direct-to-consumer and B2B insights, and a consumer product commercialization engine.

ProPhase competes in fragmented, competitive markets: in DTC genomics against 23andMe and Ancestry; in cancer diagnostics against well-funded players like Grail and Exact Sciences; and in lab services against giants like Quest and LabCorp. Its main differentiator is its hybrid, revenue-generating business model.